 Older classes of medications, though, too, have indications or benefits outside just diabetes. For instance, pioglitazone, which we've had for a long time. We know that there have been studies demonstrating benefit in reducing progression to diabetes, cardiovascular disease, also on what we used to call non-alcoholic liver disease. So I think it's important to recognize that what we're seeing with the newer classes of agents in terms of pleiotropic potential benefits is not singular to the newer classes of agents. I think it's a win-win for all of us.